BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 31088790)

  • 1. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials.
    Xie W; Huang Y; Xiao S; Sun X; Fan Y; Zhang Z
    Ann Rheum Dis; 2019 Aug; 78(8):1048-1054. PubMed ID: 31088790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Wang F; Sun L; Wang S; Davis JM; Matteson EL; Murad MH; Luo F; Vassallo R
    Mayo Clin Proc; 2020 Jul; 95(7):1404-1419. PubMed ID: 32499126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current jakinibs for the treatment of rheumatoid arthritis: a systematic review.
    Rocha CM; Alves AM; Bettanin BF; Majolo F; Gehringer M; Laufer S; Goettert MI
    Inflammopharmacology; 2021 Jun; 29(3):595-615. PubMed ID: 34046798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box.
    Misra DP; Pande G; Agarwal V
    Clin Rheumatol; 2023 Feb; 42(2):621-632. PubMed ID: 36264400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Song GG; Choi SJ; Lee YH
    Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
    Jegatheeswaran J; Turk M; Pope JE
    Immunotherapy; 2019 Jun; 11(8):737-754. PubMed ID: 30955397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
    Yang F; Lu C; Wang Y; Liu H; Leng X; Zeng X
    Clin Rheumatol; 2023 Jun; 42(6):1593-1605. PubMed ID: 36763226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
    Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
    Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.
    Kunwar S; Collins CE; Constantinescu F
    Clin Rheumatol; 2018 Oct; 37(10):2611-2620. PubMed ID: 30006916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of jakinibs in rheumatoid arthritis: a systematic review and meta-analysis.
    Yin Y; Liu M; Zhou E; Chang X; He M; Wang M; Wu J
    Clin Rheumatol; 2021 Oct; 40(10):3989-4005. PubMed ID: 33990888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.
    Bechman K; Subesinghe S; Norton S; Atzeni F; Galli M; Cope AP; Winthrop KL; Galloway JB
    Rheumatology (Oxford); 2019 Oct; 58(10):1755-1766. PubMed ID: 30982883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In brief: New warnings for janus kinase inhibitors.
    Med Lett Drugs Ther; 2021 Oct; 63(1634):160. PubMed ID: 34550959
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
    Taylor PC; Takeuchi T; Burmester GR; Durez P; Smolen JS; Deberdt W; Issa M; Terres JR; Bello N; Winthrop KL
    Ann Rheum Dis; 2022 Mar; 81(3):335-343. PubMed ID: 34706874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials.
    Qiu C; Zhao X; She L; Shi Z; Deng Z; Tan L; Tu X; Jiang S; Tang B
    Lipids Health Dis; 2019 Feb; 18(1):54. PubMed ID: 30777075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.
    Solipuram V; Mohan A; Patel R; Ni R
    Auto Immun Highlights; 2021 Apr; 12(1):8. PubMed ID: 33910632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: a systematic review and network meta-analysis of randomized controlled trials.
    Cai W; Tong R; Sun Y; Yao Y; Zhang J
    Front Pharmacol; 2024; 15():1387585. PubMed ID: 38725657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
    Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials.
    Xie W; Xiao S; Huang Y; Sun X; Zhang Z
    Ther Adv Musculoskelet Dis; 2019; 11():1759720X19895492. PubMed ID: 31897092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis.
    Taylor PC; Weinblatt ME; Burmester GR; Rooney TP; Witt S; Walls CD; Issa M; Salinas CA; Saifan C; Zhang X; Cardoso A; González-Gay MA; Takeuchi T
    Arthritis Rheumatol; 2019 Jul; 71(7):1042-1055. PubMed ID: 30663869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Cardiovascular and Venous Thromboembolic Events Associated With Janus Kinase Inhibitors in Rheumatoid Arthritis: A Systematic Review and Network Meta-analysis.
    Alves C; Penedones A; Mendes D; Marques FB
    J Clin Rheumatol; 2022 Mar; 28(2):69-76. PubMed ID: 34741000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.